IMPACT OF TUMOUR INFILTRATING LYMPHOCYTES (TILS) & TUMOUR REGRESSION IN PRIMARY CUTANEOUS MELANOMA ON RESPONSE TO IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY

被引:0
|
作者
Mcmullen, Michelle [1 ]
Martin, Hilary [1 ,2 ]
Tan, Rebekah [2 ]
Leng, Weijie [2 ]
Ohara, Kanako [1 ]
Khattak, Muhammad [1 ,2 ,3 ]
机构
[1] Fiona Stanley Hosp, Wembley, WA, Australia
[2] Univ Western Australia, Perth, WA, Australia
[3] Edith Cowan Univ, Perth, WA, Australia
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
203
引用
收藏
页码:113 / 113
页数:1
相关论文
共 50 条
  • [41] TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer
    Koh, Jaemoon
    Kim, Sehui
    Woo, Yeon Duk
    Song, Seung Geun
    Yim, Jeemin
    Han, Bogyeong
    Lim, Sojung
    Ahn, Hyun Kyung
    Mun, Seungchan
    Kim, Jung Sun
    Keam, Bhumsuk
    Kim, Young A.
    Lee, Se-Hoon
    Jeon, Yoon Kyung
    Chung, Doo Hyun
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : 10 - 20
  • [42] REPRODUCTIVE IMPACT OF IMMUNE CHECKPOINT INHIBITOR THERAPY IN WOMEN WITH MELANOMA.
    Rhodes, Quinn
    Woodard, Terri L.
    Roth, Michael
    Detti, Laura
    Shott, Susan
    McKenzie, Laurie
    FERTILITY AND STERILITY, 2024, 122 (04) : E307 - E307
  • [43] Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma
    Esmaeli, Bita
    Ogden, Tyler
    Nichols, Matthew
    Lu, Tracy
    Debnam, J. Matthew
    Dimitriou, Florentia
    Mcquade, Jennifer
    Oliva, Isabella C. Glitza
    MELANOMA RESEARCH, 2025, 35 (02) : 130 - 144
  • [44] Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma
    Tessier, MH
    Pandolfino, MC
    Jotereau, F
    Boudart, D
    Litoux, P
    Dreno, B
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (04) : 735 - 736
  • [45] The relationship between CD204 M2-polarized tumour-associated macrophages (TAMs), tumour-infiltrating lymphocytes (TILs), and microglial activation in glioblastoma microenvironment: a novel immune checkpoint receptor target
    Kurdi, Maher
    Alghamdi, Badrah
    Butt, Nadeem Shafique
    Baeesa, Saleh
    DISCOVER ONCOLOGY, 2021, 12 (01)
  • [46] The relationship between CD204 M2-polarized tumour-associated macrophages (TAMs), tumour-infiltrating lymphocytes (TILs), and microglial activation in glioblastoma microenvironment: a novel immune checkpoint receptor target
    Maher Kurdi
    Badrah Alghamdi
    Nadeem Shafique Butt
    Saleh Baeesa
    Discover Oncology, 12
  • [47] Histologic evaluation of tumour infiltrating lymphocytes (TILs) with H&E section in primary lung adenocarcinoma: A practical method for prognostic prediction
    Lee, C. -H.
    Kim, A. -R.
    Lee, S. -J.
    Hwang, C. -S.
    Kim, Y. -K.
    Choi, K. -U.
    Park, D. -Y.
    Shin, D. -H.
    Huh, G. -Y.
    VIRCHOWS ARCHIV, 2017, 471 : S112 - S112
  • [48] Tumour infiltrating lymphocytes as a predictive factor for the response to adjuvant endocrine therapy in early breast cancer
    Blok, E.
    Engels, C.
    Jongste, E.
    Dekker-Ensink, G.
    Kroep, J.
    Kuppen, P.
    Van de Velde, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S323 - S323
  • [49] Responses to immune checkpoint inhibitor therapy in NF1 mutated cutaneous melanoma
    Kroll, Matthew Robert
    Snow, Anthony N.
    Loeffler, Bradley T.
    Milhem, Mohammed M.
    Javed, Asad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
    van Duin, Isabella A. J.
    Schuiveling, Mark
    Maat, Laurens S. ter
    van Amsterdam, Wouter A. C.
    van den Berkmortel, Franchette
    Boers-Sonderen, Marye
    de Groot, Jan Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Labots, Mariette
    Piersma, Djura
    Schrader, Anne M. R.
    Vreugdenhil, Gerard
    Westgeest, Hans
    Veta, Mitko
    Blokx, Willeke A. M.
    van Diest, Paul J.
    Suijkerbuijk, Karijn P. M.
    EUROPEAN JOURNAL OF CANCER, 2024, 208